Aadi Bioscience Inc
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form of 10-K Summary
We may voluntarily include a summary of information required by Form 10-K under this Item 16. We have elected not to include such summary information.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AADI BIOSCIENCE, INC. | ||
| Date: March 13, 2024 | By: | /s/ David J. Lennon |
|---|---|---|
| David J. Lennon, Ph.D. | ||
| Chief Executive Officer and President(Principal Executive Officer) | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David J. Lennon, Ph.D., Scott Giacobello and Stephen Rodin, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ David J. Lennon | Chief Executive Officer and President and Director(Principal Executive Officer) | March 13, 2024 |
| David J. Lennon, Ph.D. | ||
| /s/ Scott Giacobello | Chief Financial Officer(Principal Financial and Accounting Officer) | March 13, 2024 |
| Scott Giacobello | ||
| /s/ Caley Castelein | Chairman | March 13, 2024 |
| Caley Castelein, M.D. | ||
| /s/ Behzad Aghazadeh | Director | March 13, 2024 |
| Behzad Aghazadeh, Ph.D. | ||
| /s/ Anupam Dalal | Director | March 13, 2024 |
| Anupam Dalal, M.D. | ||
| /s/ Neil Desai | Director; Executive Chairman | March 13, 2024 |
| Neil Desai, Ph.D. | ||
| /s/ Karin Hehenberger | Director | March 13, 2024 |
| Karin Hehenberger, M.D., Ph.D. | ||
| /s/ Mohammad Hirmand | Director | March 13, 2024 |
| Mohammad Hirmand, M.D. | ||
| /s/ Richard Maroun | Director | March 13, 2024 |
| Richard Maroun, J.D. | ||
| /s/ Emma Reeve | Director | March 13, 2024 |
| Emma Reeve | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.